In order to achieve greater patient participation, the FAMHP has decided to extend its survey on the use of benzodiazepines and similar in the context of sleep disorders in Belgium by two months. The survey will therefore be accessible until 19 May 2020 inclusive.

During its meeting of March 2020, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended the suspension of ulipristal acetate for uterine fibroids during ongoing review of liver injury risk. Furthermore, the PRAC made new testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine, and started a review of certain ifosfamide cancer medicines.

Certain stocks of over-the-counter medicinal products have been selling out rapidly in Belgian pharmacies recently as many citizens are stocking up on medicinal products. There are still sufficient wholesale stocks of medicinal products in Belgium, but to avoid a shortage, the FAMHP asks all citizens not to pointlessly stock up on medicinal products.

The FAMHP is closely monitoring stocks of medicinal products used in the fight against COVID-19. Certain of these medicinal products are essential to treat patients with chronic diseases (e.g. lupus, rhumatoid arthritis, HIV, etc.). The FAMHP is taking measures to guarantee the availability of these essential medicines.

Due to the coronavirus problem and potentially overloaded hospitals, it may be difficult or undesirable for a patient participating in a clinical trial to obtain their investigational medicinal product (IMP) at the hospital. The FAMHP provides guidelines on this subject.

Last updated on 29/06/2017